Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Methionine adenosyltransferase (MAT), also known as S-adenosylmethionine synthetase, is a key enzyme in cellular metabolism that catalyzes the synthesis of S-adenosylmethionine (SAM or AdoMet) from methionine and ATP. SAM is the principal biological methyl donor, essential for transmethylation reactions affecting DNA, proteins, lipids, and other small molecules. Dysregulation of MAT activity has been implicated in several diseases including liver disorders/injury and cancer progression/metastasis. Targeting specific MAT isoforms has become an area of interest for drug development against cancer, neurodegenerative diseases, depression, osteoarthritis, migraine, among others.
Inhibition of SAM synthesis by targeting MAT isoforms
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Methionine Adenosyltransferase.